In a nutshell This study compared nivolumab (Opdivo) plus ipilimumab (Yervoy) to either drug alone for the treatment of advanced melanoma. The authors concluded that nivolumab plus ipilimumab or nivolumab alone increased survival compared to ipilimumab alone for these patients. Some background Advanced melanoma is a type of skin cancer that...
Read More
In a nutshell This study investigated if atezolizumab (Tecentriq) combined with chemotherapy (CT) is effective in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC). They found that this treatment improved survival in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common lung cancer...
Read More
In a nutshell This study is examining the effectiveness of biological drug sacituzumab govitecan (IMMU-132) compared to standard treatments for patients with hormone receptor-positive metastatic breast cancer. The main outcomes that will be measured are cancer responsiveness to the drug and survival of patients without the cancer growing. This trial...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of standard therapy alone or combined with new drugs as first line treatment for advanced colorectal cancer. The main outcome to be measured will be safety and tumor response to the treatment. The details Colorectal cancer is one of the most common cancers worldwide. A significant...
Read More
In a nutshell This phase 1/2 trial will investigate the safety of OBT076 in patients with advanced breast cancer. The main outcomes will be the frequency of side effects and response to treatment. This trial is recruiting at Columbia University Medical Center, NY, US. The details Breast cancer (BC) is a highly treatable...
Read More
In a nutshell This study investigated the effectiveness and safety of increasing doses of regorafenib (Stivarga) doses in patients with advanced colorectal cancer. Researchers suggested that this method with increasing doses should be used to assess the optimal dose for each patient. Some background Colorectal cancer is the third most common cancer...
Read More
In a nutshell This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results. Some background...
Read More
In a nutshell This trial is examining the effectiveness of pegilodecakin (AM0010) when it is used with pembrolizumab (Keytruda) to treat patients with advanced non-small cell lung cancer (NSCLC). The main outcome to be measured will be tumor responses to the treatment. This trial is recruiting in multiple locations around the United States. The...
Read More
In a nutshell This study compared the long-term outcomes of two targeted therapies for patients with advanced melanoma. This study concluded that pembrolizumab (Keytruda) was more effective than ipilimumab (Yervoy) for these patients, with a similar rate of side effects. Some background Advanced melanoma is a type of skin cancer...
Read MoreIn a nutshell This phase 2b trial will evaluate ModraDoc006 (MOD) in patients with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes will be the objective response rate (ORR). This trial is recruiting at a number of locations in the US. The details Metastatic castration-resistant prostate cancer (mCRPC) is...
Read More
In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...
Read More
In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer. This study concluded that these side effects do not impact the outcomes for these patients. Some background...
Read More
